Incyte Pronounces Optimistic Outcomes from Part 3 Trial Evaluating Retifanlimab (Zynyz ®) in Mixture with Platinum-Primarily based Chemotherapy in Sufferers with Non-Small Cell Lung Most cancers
” Part 3 POD1UM-304 trial met major endpoint of total survival (OS) and all secondary endpoints ...
Read more
